XML 40 R29.htm IDEA: XBRL DOCUMENT v3.19.1
Mezzanine and Stockholders' Equity (Tables)
3 Months Ended
Mar. 31, 2019
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions
During the three months ended March 31, 2019, the Company granted 45,000 stock options to certain ApolloMed board members which were recognized at fair value, as determined using the Black-Scholes option pricing model and the following assumptions:
 
 
 
 
March 31,

2019
 
 
 
 
 
Expected Term
 
 
3.0
years
 
Expected volatility
 
 
100.27
%
 
Risk-free interest rate
 
 
2.51
%
 
Market value of common stock
 
$
18.11
 
Annual dividend yield
 
 
-
 
Forfeiture rate
 
 
0
%
Summary of Share-Based Compensation Expense of Stock Option Awards Granted
Share-based compensation expense related to option awards granted to primary care physicians to purchase shares of APC’s common stock, are recognized over their respective vesting periods, and consisted of the following:
 
 
 
Three Months Ended

March 31,
 
 
 
2019
 
 
2018
 
Share-based compensation expense:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
General and administrative
 
$
202,382
 
 
$
202,382
 
 
 
 
 
 
 
 
 
 
 
 
$
202,382
 
 
$
202,382
 
Warrants Outstanding
The Company’s outstanding warrants consisted of the following:
 
 
 
Shares
 
 
Weighted

Average

Exercise Price
 
 
Weighted

Average

Remaining

Contractual

Term

(Years)
 
 
Aggregate

Intrinsic

Value
(in millions)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Warrants outstanding at January 1, 2019
 
 
3,331,995
 
 
$
9.93
 
 
 
2.97
 
 
$
33.1
 
Warrants granted
 
 
-
 
 
 
-
 
 
 
-
 
 
 
-
 
Warrants exercised
 
 
(11,516
)
 
 
9.81
 
 
 
-
 
 
 
0.1
 
Warrants expired/forfeited
 
 
-
 
 
 
-
 
 
 
-
 
 
 
-
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Warrants outstanding at March 31, 2019
 
 
3,320,479
 
 
$
9.93
 
 
 
2.72
 
 
$
27.9
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Weighted
 
 
 
 
 
 
 
Weighted
 
 
 
 
 
Average
 
 
 
 
 
 
 
Average
 
 
 
 
 
Exercise Price
 
Exercise Price Per
 
 
Warrants
 
 
Remaining
 
 
Warrants
 
 
Per
 
Share
 
 
Outstanding
 
 
Contractual Life
 
 
Exercisable
 
 
Share
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
$
9.00
 
 
 
1,075,492
 
 
 
1.54
 
 
 
1,075,492
 
 
 
9.00
 
 
10.00
 
 
 
1,416,085
 
 
 
3.04
 
 
 
1,416,085
 
 
 
10.00
 
 
11.00
 
 
 
828,902
 
 
 
3.69
 
 
 
828,902
 
 
 
11.00
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
$
9.00 –11.00
 
 
 
3,320,479
 
 
 
2.72
 
 
 
3,320,479
 
 
$
9.93
 
Exclusivity Amendment Agreement, APC [Member]  
Stock Option Transactions Under Stock Option Plans
Outstanding stock options granted to primary care physicians to purchase shares of APC’s common stock consisted of the following:
    
 
 
Shares
 
 
Weighted

Average

Exercise Price
 
 
Weighted

Average

Remaining

Contractual

Term

(Years)
 
 
Aggregate

Intrinsic

Value
(in millions)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Options outstanding at January 1, 2019
 
 
853,800
 
 
$
0.167
 
 
 
0.75
 
 
$
0.5
 
Options granted
 
 
-
 
 
 
-
 
 
 
-
 
 
 
-
 
Options exercised
 
 
-
 
 
 
-
 
 
 
-
 
 
 
-
 
Options expired/forfeited
 
 
-
 
 
 
-
 
 
 
-
 
 
 
-
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Options outstanding and exercisable at March 31, 2019
 
 
853,800
 
 
$
0.167
 
 
 
0.50
 
 
$
0.5
 
Employee Stock Option [Member]  
Stock Option Transactions Under Stock Option Plans
The Company’s outstanding stock options consisted of the following:
 
 
 
Shares
 
 
Weighted

Average

Exercise Price
 
 
Weighted

Average

Remaining

Contractual

Term

(Years)
 
 
Aggregate

Intrinsic

Value
(in millions)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Options outstanding at January 1, 2019
 
 
647,240
 
 
$
5.62
 
 
 
4.13
 
 
$
9.2
 
Options granted
 
 
45,000
 
 
 
18.11
 
 
 
-
 
 
 
-
 
Options exercised
 
 
(6,000
)
 
 
4.50
 
 
 
-
 
 
 
0.1
 
Options forfeited
 
 
-
 
 
 
-
 
 
 
-
 
 
 
-
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Options outstanding at March 31, 2019
 
 
686,240
 
 
$
6.45
 
 
 
3.95
 
 
$
8.1
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Options exercisable at March 31, 2019
 
 
641,240
 
 
$
5.27
 
 
 
3.64
 
 
$
8.1